Regorafenib in patients with recurrent high-grade astrocytoma

Purpose Antiangiogenic treatment approaches have failed to improve outcome in randomized trials of high-grade astrocytoma. One key mechanism of resistance to antiangiogenic treatment may concern the upregulation of alternative pro-angiogenic pathways. Regorafenib is a potent multikinase inhibitor th...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of cancer research and clinical oncology 2019-04, Vol.145 (4), p.1037-1042
Hauptverfasser:	Kebir, Sied, Rauschenbach, Laurel, Radbruch, Alexander, Lazaridis, Lazaros, Schmidt, Teresa, Stoppek, Ann-Kathrin, Pierscianek, Daniela, Stuschke, Martin, Forsting, Michael, Sure, Ulrich, Keyvani, Kathy, Kleinschnitz, Christoph, Scheffler, Björn, Glas, Martin
Format:	Artikel
Sprache:	eng
Schlagworte:	Angiogenesis Astrocytoma Cancer Research Clinical trials Glioma Growth patterns Hematology Internal Medicine Medicine Medicine & Public Health Oncology Original Article – Clinical Oncology Patients Survival Targeted cancer therapy Toxicity
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!